FBR Capital analyst William Tanner reiterated a Market Perform rating and slashed his price target on Sarepta Therapeutic (NASDAQ: SRPT) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Deutsche Bank Cuts Sarepta Therapeutic (SRPT) to Hold, PT $17November 12, 2013 3:54 PM Sarepta (SRPT) Target Cut to $45 at Wedbush, Analyst Expects Larger Eteplirsen TrialNovember 12, 2013 2:22 PM Needham & Company Downgrades Sarepta Therapeutic (SRPT) to HoldNovember 12, 2013 12:46 PM Sarepta (SRPT) Eteplirsen Delay Impacts DCF by $10/sh Each Year - Deutsche BankNovember 12, 2013 9:25 AM Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to UnderweightNovember 12, 2013 8:11 AM FDA Considers Sarepta's (SRPT) NDA for Eteplirsen 'Premature'November 12, 2013 7:05 AM